 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
The exact way metformin works is unclear, but the drug also appears to improve or correct other conditions associated with the metabolic syndrome, such as high fat levels in the blood, the way calcium enters cells, blood clotting abnormalities, and obesity. When compared with conventional diabetes therapy, metformin significantly reduces the risk for heart attack, diabetes-related death, and overall death. Metformin is especially well suited for treatment of obese diabetic persons with normal kidney function. The drug may not be appropriate for thin elderly patients.
Dose of the drug should be increased gradually to allow the body to adjust to its effects. Common side effects are nausea and diarrhea, which usually disappear within 2 weeks. Metformin may be associated with a life-threatening buildup of lactic acid in the blood (lactic acidosis) and is not appropriate for people with liver failure, a history of alcohol abuse, or active infections.
SUMMARIES FOR PATIENTS
Metformin for Patients with Type 2 Diabetes Mellitus
2 July 2002 | Volume 137 Issue 1 | Page I-50
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Metformin: An Update." It is in the 2 July 2002 issue of Annals of Internal Medicine (volume 137, pages 25-33). The authors are D Kirpichnikov, SI McFarlane, and JR Sowers.
What is the problem and what is known about it so far?
Diabetes mellitus is a disease characterized by high levels of sugar (glucose) in the blood. Insulin (a chemical produced by the pancreas) helps regulate the level of glucose in the blood by facilitating its passage into the cells of the body, where it is used as a nutrient. When glucose enters cells, it is effectively removed from the blood and its concentration in the bloodstream decreases. Two types of diabetes mellitus are recognized. Type 1 (juvenile) diabetes is caused by a failure of the pancreas to produce insulin, while type 2 (adult-onset or non-insulin-dependent) diabetes results from resistance of cells to respond to insulin's usual effects. Although extra insulin output initially overcomes cells' resistance, the pancreas eventually fails to produce enough to do the job effectively. Many experts believe that type 2 diabetes is one component of a "metabolic syndrome" that includes obesity, cholesterol disorders, hypertension, and blood clotting abnormalities.
Why did the authors do this update?
To update doctors on the effectiveness of metformin, a drug used to treat high blood sugar and other components of the metabolic syndrome.
How did the authors do this update?
They looked at numerous studies that followed patients treated with metformin alone or in combination with other drugs and articles dealing with the metabolic syndrome.
What did the authors find?
Metformin is effective in decreasing cells' resistance to insulin. By itself, metformin is as effective as another group of drugs used to lower blood sugar (sulfonylureas), and when used along with diet modification, it substantially reduces the fasting blood sugar level. When taken in combination with other agents, it is frequently more effective than any single drug used to lower blood glucose levels.
What are the implications of this update?
Physicians should consider prescribing metformin, alone or in combination with other therapies, for patients with type 2 diabetes mellitus, particularly those who are obese and have normal kidney function.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  Y. Hong, S. Rohatagi, B. Habtemariam, J. R. Walker, S. L. Schwartz, and D. E. Mager Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus J. Clin. Pharmacol., June 1, 2008; 48(6): 696 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rowan, W. M. Hague, W. Gao, M. R. Battin, M. P. Moore, and the MiG Trial Investigators Metformin versus Insulin for the Treatment of Gestational Diabetes N. Engl. J. Med., May 8, 2008; 358(19): 2003 - 2015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Calvert, S. Gundewar, S. Jha, J. J.M. Greer, W. H. Bestermann, R. Tian, and D. J. Lefer Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS-Mediated Signaling Diabetes, March 1, 2008; 57(3): 696 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. D. Kim, K.-G. Park, Y.-S. Lee, Y.-Y. Park, D.-K. Kim, B. Nedumaran, W. G. Jang, W.-J. Cho, J. Ha, I.-K. Lee, et al. Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP Diabetes, February 1, 2008; 57(2): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Basu, P. Shah, A. Basu, B. Norby, B. Dicke, V. Chandramouli, O. Cohen, B. R. Landau, and R. A. Rizza Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes Diabetes, January 1, 2008; 57(1): 24 - 31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Odegard, S. M. Setter, and J. J. Neumiller Considerations for the Pharmacological Treatment of Diabetes in Older Adults Diabetes Spectr, October 1, 2007; 20(4): 239 - 247. [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Rowan and on behalf of the MiG Investigators A Trial in Progress: Gestational Diabetes: Treatment with metformin compared with insulin (the Metformin in Gestational Diabetes [MiG] trial) Diabetes Care, July 1, 2007; 30(Supplement_2): S214 - S219. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Kitzmiller, L. Dang-Kilduff, and M. M. Taslimi Gestational Diabetes After Delivery: Short-term management and long-term risks Diabetes Care, July 1, 2007; 30(Supplement_2): S225 - S235. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Serlie, G. Allick, J. E. Groener, M. T. Ackermans, R. Heijligenberg, B. C. Voermans, J. M. Aerts, A. J. Meijer, and H. P. Sauerwein Chronic Treatment with Pioglitazone Does Not Protect Obese Patients with Diabetes Mellitus Type II from Free Fatty Acid-Induced Insulin Resistance J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 166 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Karim, M. Slater, D. Bradford, L. Schwartz, Z. Zhao, C. Cao, and A. Laurent Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed-Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug J. Clin. Pharmacol., January 1, 2007; 47(1): 37 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Suwa, T. Egashira, H. Nakano, H. Sasaki, and S. Kumagai Metformin increases the PGC-1{alpha} protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo J Appl Physiol, December 1, 2006; 101(6): 1685 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Koski Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus The Diabetes Educator, November 1, 2006; 32(6): 869 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Walker, M. Molitch, M. K. Kramer, S. Kahn, Y. Ma, S. Edelstein, K. Smith, M. K. Johnson, A. Kitabchi, J. Crandall, et al. Adherence to Preventive Medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care, September 1, 2006; 29(9): 1997 - 2002. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Friesecke, P. Abel, M. Kraft, A. Gerner, and S. Runge Combined renal replacement therapy for severe metformin-induced lactic acidosis Nephrol. Dial. Transplant., July 1, 2006; 21(7): 2038 - 2039. [Full Text] [PDF]
|
|
|
|
|
|
A. Balasubramanyam, D. Hinnen, and W. Polonsky Cardiovascular Event Prevention in the Person With Type 2 Diabetes: Case Examples for Identifying and Treating Multiple Risks The Diabetes Educator, July 1, 2006; 32(Supplement_5): 163S - 173S. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rautio, J.S. Tapanainen, A. Ruokonen, and L.C. Morin-Papunen Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study Hum. Reprod., June 1, 2006; 21(6): 1400 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Schwartz, V. Fonseca, B. Berner, M. Cramer, Y.-K. Chiang, and A. Lewin Efficacy, Tolerability, and Safety of a Novel Once-Daily Extended-Release Metformin in Patients With Type 2 Diabetes Diabetes Care, April 1, 2006; 29(4): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Dhahbi, P. L. Mote, G. M. Fahy, and S. R. Spindler Identification of potential caloric restriction mimetics by microarray profiling Physiol Genomics, November 17, 2005; 23(3): 343 - 350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kendall, M. C. Riddle, J. Rosenstock, D. Zhuang, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea Diabetes Care, May 1, 2005; 28(5): 1083 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes Diabetes Care, May 1, 2005; 28(5): 1092 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y.Y. Cheng and I. G. Fantus Oral antihyperglycemic therapy for type 2 diabetes mellitus Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M E Tushuizen, M Diamant, and R J Heine Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes Postgrad. Med. J., January 1, 2005; 81(951): 1 - 6. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Klein, S. Westphal, D. Kraus, B. Meier, N. Perwitz, V. Ott, M. Fasshauer, and H H. Klein Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes J. Endocrinol., November 1, 2004; 183(2): 299 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Marchetti, S. Del Guerra, L. Marselli, R. Lupi, M. Masini, M. Pollera, M. Bugliani, U. Boggi, F. Vistoli, F. Mosca, et al. Pancreatic Islets from Type 2 Diabetic Patients Have Functional Defects and Increased Apoptosis That Are Ameliorated by Metformin J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5535 - 5541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Buse, R. R. Henry, J. Han, D. D. Kim, M. S. Fineman, A. D. Baron, and for the Exenatide-113 Clinical Study Group Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes Diabetes Care, November 1, 2004; 27(11): 2628 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Caballero, A. Delgado, C. A. Aguilar-Salinas, A. N. Herrera, J. L. Castillo, T. Cabrera, F. J. Gomez-Perez, and J. A. Rull The Differential Effects of Metformin on Markers of Endothelial Activation and Inflammation in Subjects with Impaired Glucose Tolerance: A Placebo-Controlled, Randomized Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3943 - 3948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Medina, L. I. Fernandez-Salazar, L. Garcia-Buey, and R. Moreno-Otero Approach to the Pathogenesis and Treatment of Nonalcoholic Steatohepatitis Diabetes Care, August 1, 2004; 27(8): 2057 - 2066. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. INGRAM, R M. ANSON, R. DE CABO, J. MAMCZARZ, M. ZHU, J. MATTISON, M. A. LANE, and G. S. ROTH Development of Calorie Restriction Mimetics as a Prolongevity Strategy Ann. N.Y. Acad. Sci., June 1, 2004; 1019(1): 412 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Nylen and B. Muller Endocrine Changes in Critical Illness J Intensive Care Med, March 1, 2004; 19(2): 67 - 82. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Benavides and M. C Nahata Pharmacologic Therapy for HIV-Associated Lipodystrophy Ann. Pharmacother., March 1, 2004; 38(3): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Koski Oral Antidiabetic Agents: A Comparative Review Journal of Pharmacy Practice, February 1, 2004; 17(1): 39 - 48. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Wolf and E. Ritz Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1396 - 1405. [Full Text] [PDF]
|
|
|
|
|
|
The Diabetes Prevention Program Research Group Effects of Withdrawal From Metformin on the Development of Diabetes in the Diabetes Prevention Program Diabetes Care, April 1, 2003; 26(4): 977 - 980. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
